Navigation Links
Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
Date:2/19/2008

s in Huntington's disease if the

results of the ongoing Phase 2 clinical trial are supportive.

-- Report additional follow-up data from the first pivotal trial of

Dimebon in AD.

-- Report data on Dimebon's novel mechanism of action.

-- Complete the ongoing Phase 1-2 clinical trial of MDV3100 in HRPC.

About Medivation

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company's strategy is to identify promising product candidates, to develop them in a rapid, cost-effective manner, and to seek development and/or commercialization partners as appropriate to complement its internal efforts. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Furthermore, as is typically the case at this stage of the regulatory review process, the FDA has not yet performed an in-depth review of Medivation's preclinical and clinical data, so its views remain subject to change. Medivation's filings with the Securities and Exchange Commission, including its Annual Repor
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
3. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
4. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
5. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
6. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
7. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
8. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
9. Escalon(R) Reports Second Quarter Fiscal 2008 Results
10. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
11. Eklin Medical Reports Record Revenues for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... time, chemists have succeeded in measuring vibrational motion of ... study reveals how vibration of a single molecule differs ... The study was performed at the University of California, ... of Jyvskyl works as a visiting fellow under professor ... The second team was lead by Professor Eric O. ...
(Date:8/20/2014)... California (PRWEB) August 20, 2014 ... develop and apply the most complete climate and ... and demanding climate change issues. , Eight national ... forces with the National Center for Atmospheric Research, ... the new effort. Other participating national laboratories include ...
(Date:8/20/2014)... , Aug. 20, 2014  PAREXEL International Corporation ... will be presenting at the Baird Healthcare Conference in ... and Chief Financial Officer, will be making a presentation ... EDT on Wednesday, Sept. 3, 2014. A ... the "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
(Date:8/20/2014)... Not long ago, it was more or less ... in the development cycle – even after the final ... that, like many things GxP, expectations for early E&L ... drug sponsors have been required by authorities to provide ... I/II. It’s not only clinical trial material containers causing ...
Breaking Biology Technology:Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... Kit produces cDNA , ideal for ... performed using real-time RT-PCR. The Cells-to-cDNA Kit comes in an , ... cells without RNA isolation in less than 2 ... Cell Lysis Buffer that inactivates RNases, RT-PCR can , ...
... , ... , Removes trace quantities of , ... RNase-free and recombinant in , ... lower in RNase activity than bovine pancreas , ...
... , ... , DNase enhancer increases the potency of TURBO DNase by ... , Remove DNase from RNA solutions in 5 minutes without phenol, alcohol, , ... TURBO DNase is RNase-free and recombinant in origin , The ...
Cached Biology Technology:Your Data: Detection of Oocyte-specific Gene Expression Using Ambion's Cells-to-cDNA Kit 2TURBO DNase: Hyperactive, Salt Tolerant DNase 2TURBO DNase: Hyperactive, Salt Tolerant DNase 3TURBO DNase: Hyperactive, Salt Tolerant DNase 4TURBO DNase: Hyperactive, Salt Tolerant DNase 5The World's Best DNase Improved TURBO DNA-free 2The World's Best DNase Improved TURBO DNA-free 3The World's Best DNase Improved TURBO DNA-free 4The World's Best DNase Improved TURBO DNA-free 5
(Date:8/21/2014)... a novel and versatile modeling strategy to simulate polyelectrolyte ... as well as for studying polyelectrolytes, including DNA and ... much larger and more complex polyelectrolyte systems, and to ... author of a paper on the work and a ... and Engineering. "This is a big step forward for ...
(Date:8/20/2014)... N.Y. In a study of 158 pregnant teenagers ... the craving and intentional consumption of ice, cornstarch, vacuum ... reports a new Cornell study. , Moreover, such teens ... who did not eat nonfood substances. , Pregnant teens, ... hemoglobin, which can lead to iron deficiency and anemia. ...
(Date:8/20/2014)... 20, 2014 /CNW/ -  Issue Serious ... quickly become life threatening for some children.    ... million Canadians have food allergies and this number may be ... children are estimated to have food allergies.  ... irritations and hives to breathing difficulties and loss of consciousness. ...
Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2Pica in pregnant teens linked to low iron 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... Christian Koos has succeeded in developing a novel optical ... transmission rates in the range of several terabits per ... industrial scale. In the future, this technology may be ... and, thus, contribute to reducing energy consumption of the ...
... the first researchers to study the deadly link between ... Association lifetime achievement award today at a ceremony in ... endocrinologist James Sowers, MD, recognizes his more than 30 ... The Irvine Page-Alva Bradley Lifetime Achievement Award in ...
... question about it they,re very good at what they do. ... to carry out inspection work in oily or dangerous environments, ... Still, they,re one of the fastest and most maneuverable ... and low speeds due to their streamlined bodies and a ...
Cached Biology News:Optical waveguide connects semiconductor chips 2Pioneering researcher receives Heart Association Lifetime Achievement Award 2Pioneering researcher receives Heart Association Lifetime Achievement Award 3Robotic tuna is built by Homeland Security 2